Internal medicine news - IBS
NATIONAL HARBOR, MD. – "Food is what patients
blame for their gastrointestinal symptoms," Dr. Peter Gibson said at the
annual meeting of the American College of Gastroenterology.
And patients with functional GI disorders may be on
the right track, according to Dr. Gibson, professor of medicine at
Monash University in Victoria, Australia. He presented a novel dietary
treatment that is not well known in the United States but appears
promising as a strategy for managing irritable bowel syndrome (IBS) and
other functional GI problems.
Dr. Gibson also said that physicians who want to
help their patients manage their symptoms need to understand how foods
can interact with the enteric nervous system, which controls most GI
functions.
More specifically, certain types of sugars found in
many foods are rapidly absorbed and fermented, drawing liquid into the
GI tract, which can cause distension and trigger the symptoms of IBS,
such as bloating and pain, he said.
The novel dietary approach is known by the acronym
FODMAP, which stands for the types of sugars suspected of causing
symptoms: fermentable sugars, oligosaccharides, disaccharides,
monosaccharides, and polyols (such as sorbitol or mannitol). Thus the
regimen designed to reduce symptoms is called a low-FODMAP diet, said
Dr. Gibson.
Data are limited, but in theory, a low-FODMAP diet
causes less distension of the intestinal lumen and thereby reduces IBS
symptoms. His colleague, Susan Shepherd, Ph.D., who is a dietitian, has
developed a list of foods that should be included, and others to
exclude, when following such a diet.
In a recent study, 82 IBS patients were randomized
to receive either standard dietary advice (39 people) or instruction on
following a low-FODMAP diet (43 people); the patients were meeting with a
dietitian on an outpatient basis (J. Hum. Nutr. Diet 2011;24:487-95).
Composite IBS symptom scores showed that
significantly more patients in the low-FODMAP group had overall
improvement in their symptoms, compared with the standard care group
(86% vs. 49%). In addition, significantly more low-FODMAP patients
reported improvements in bloating (82%), abdominal pain (85%), and
flatulence (87%), compared with the standard care group (49%, 61%, and
50%, respectively).
More research is needed, but the data support the potential effectiveness of a low-FODMAP diet, Dr. Gibson said.
Some examples of foods to include as part of a
low-FODMAP diet are bananas, blueberries, artichokes, green beans,
lettuce, potatoes, gluten-free bread or cereal products, rice, oats,
hard cheeses, lactose-free milk, sugar, molasses, and any artificial
sweeteners with names that do not end in "ol."
(c) Christian Pedant/fotolia.com
Patients should steer clear of these fruits when embarking on the low-FODMAP diet to help with irritable bowl syndrome. |
Foods
to eliminate when following a low-FODMAP diet include apples, pears,
canned fruit in natural juice, high-fructose corn syrup, cows’ milk
(which contains lactose), soft cheese, broccoli, cabbage, pasta, bread,
or baked goods made from wheat or rye, mushrooms, and sweeteners ending
in "ol," such as sorbitol.
A potential limitation of using the low-FODMAP diet
is that it requires collaboration with a dietitian who is familiar with
the diet, Dr. Gibson noted, and the diet is relatively unknown in the
United States.
However, it may catch on, Dr. William D. Chey said
in an interview at the meeting. Dr. Chey is a professor of internal
medicine and director of the gastrointestinal physiology laboratory at
the University of Michigan in Ann Arbor; he is also one of the two
editors in chief of the American Journal of Gastroenterology.
"I think doctors are hungry for non-medical
interventions" for IBS patients, Dr. Chey said. Although the diet is
restrictive, many IBS patients are already on such restricted diets that
the low-FODMAP diet actually broadens their food choices, which may
promote adherence, he added.
More details about the low-FODMAP diet, including a
complete list of foods and a database of knowledgeable dietitians, are
available at ibsgroup.org/ibs-diet.
Dr. Gibson said he had no relevant financial
disclosures. Dr. Chey has served as a consultant for multiple companies
including AstraZeneca, Johnson & Johnson, Salix, and Takeda.
No comments:
Post a Comment